While most FDA-approved immunotherapies target CD8+ cytotoxic T cells, the role of CD4+ helper T cells [38, 39] and CD163+ macrophages [40–42] is less well defined but increasingly seen as key players in the breast cancer microenvironment. Here, CD163 is linked to breast carcinoma.